<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>For progression to clinical trials in <z:hpo ids='HP_0001297'>stroke</z:hpo>, putative neuroprotective compounds should show robust efficacy post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> in several experimental models of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This paper describes the characterisation of (+)(1S, 2R)-cis-1-[4-(1-<z:chebi fb="36" ids="29309">methyl</z:chebi>-1-phenylethyl)phenoxy]-2-<z:chebi fb="0" ids="44209">methylamino</z:chebi> <z:chebi fb="0" ids="37911">indane</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> (SB-221420-A), a Ca(2+) and <z:chebi fb="0" ids="29101">Na(+)</z:chebi> channel <z:chebi fb="68" ids="48706">antagonist</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>SB-221420-A inhibited (IC(50)=2.2 microM) N-type voltage-operated Ca(2+) channel currents in cultured superior cervical ganglion neurons, which were pretreated with 10 microM nimodipine to block L-type voltage-operated Ca(2+) channel currents </plain></SENT>
<SENT sid="3" pm="."><plain>In dorsal root ganglion neurons pretreated with 1 microM omega-conotoxin GVIA to block N-type voltage-operated Ca(2+) channel currents, SB-221420-A inhibited the residual Ca(2+) current with an IC(50) of 7 microM </plain></SENT>
<SENT sid="4" pm="."><plain>SB-221420-A also inhibited <z:chebi fb="0" ids="29101">Na(+)</z:chebi> currents in dorsal root ganglion neurons with an IC(50) of 8 microM </plain></SENT>
<SENT sid="5" pm="."><plain>In rats, the pharmacokinetic profile of SB-221420-A shows that it has a half-life of 6.4 h, a high volume of distribution, is highly brain penetrating, and has no persistent metabolites </plain></SENT>
<SENT sid="6" pm="."><plain>Following bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> in gerbils, SB-221420-A significantly reduced the level of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced hyperlocomotor activity and the extent of hippocampal CA1 cell loss compared to the ischaemic vehicle-treated group </plain></SENT>
<SENT sid="7" pm="."><plain>SB-221420-A was also effective in focal models of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In the mouse permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model, SB-221420-A (10 mg/kg) administered intravenously, post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> significantly (P&lt;0.05) reduced lesion volume compared to the ischaemic vehicle-treated group </plain></SENT>
<SENT sid="9" pm="."><plain>In the normotensive rat permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model, SB-221420-A (10 mg/kg) administered intravenously over 1 h, beginning 30 min postmiddle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, significantly (P&lt;0.05) reduced lesion volume from 291+/-16 to 153+/-30 mm(3), compared to ischaemic vehicle-treated controls when measured 24 h postmiddle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Efficacy was maintained when the same total dose of SB-221420-A was infused over a 6-h period, beginning 30 min postmiddle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="11" pm="."><plain>SB-221420-A also significantly (P&lt;0.05) reduced lesion volume following transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in normotensive rats and permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in spontaneously hypertensive rats (SHR) </plain></SENT>
<SENT sid="12" pm="."><plain>Investigation of the side effect profile using the Irwin screen in mice revealed that, at neuroprotective doses, there were no overt behavioural or cardiovascular changes </plain></SENT>
<SENT sid="13" pm="."><plain>These data demonstrate that robust neuroprotection can be seen post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> with SB-221420-A in both global and focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> with no adverse effects at neuroprotective doses, and indicate the potential utility of a mixed <z:chebi fb="36" ids="36916">cation</z:chebi> blocker to improve outcome in <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
</text></document>